Meanwhile, since this study is not a meta-analysis, the association of GLP-1R agonists with outcomes of patients with DPN could not be fully addressed
Prescribing Ozempic for weight loss is off-label use
Treatment plans are offered as a convenient subscription service, which you can pause or cancel at any time
In January 2024, The Obesity Society, Obesity Action Coalition and Obesity Medicine Association released a joint statement against the use of compounded and counterfeit medications
The dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes), enrolling around 10,000 participants with established cardiovascular disease, chronic kidney disease, or high CV risk, is not expected to report until 2027 at the earliest [11]
And they may want to follow you more closely or consider adjusting the dose of your medication